The SARS-CoV-2 virus is responsible for the pandemic of the disease called COVID-19. One of the peculiarities of this disease is the absence of specific drug treatments to combat it, but only drugs that act on symptoms. Several adverse effects on the cardiovascular system due to the action of the virus on the ACE-2 receptor were observed in patients hospitalized for COVID-19. Furthermore, it was observed that patients who had such effects are more likely to suffer complications in the post-cure period, which was called post-COVID syndrome-19. However, there is a lack of concrete data on the consequences of the use of certain drugs in drug treatment and its relationship with the referred syndrome. The need to better understand the long-term action of these drugs becomes even more relevant when we think about possible side effects on the cardiovascular system. Considering that complications such as myocarditis, heart failure, hypertension and myocardial arrhythmias are present in most cases of COVID-19 infection, it is necessary to study the correlation between drug treatment and worsening of these complications. The complete analysis of possible damage can be done through the observation of imaging tests directed to the cardiovascular system and specific biomarkers for each of the complications, generating data capable of, together with the analysis of medical records containing the treatment applied to each volunteer , be redirected to a statistical analysis.
News published in Agência FAPESP Newsletter about the scholarship: